History | Secukinumab for treating moderate to severe plaque psoriasis | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

Equality impact assessment - guidance development

Equality impact assessment - guidance development
Equality impact assessment - guidance development (PDF 80 KB)

Published:

22 July 2015

Final appraisal determination

Final appraisal determination information
Final appraisal determination document
Final appraisal determination document (PDF 220 KB)

Published:

29 May 2015
Committee papers information
Committee papers (PDF 6.41 MB)

Published:

29 May 2015

Psoriasis (plaque, moderate to severe) - secukinumab: equality impact assessment: scoping

Psoriasis (plaque, moderate to severe) - secukinumab: equality impact assessment: scoping
Psoriasis (plaque, moderate to severe) - secukinumab: equality impact assessment: scoping (PDF 14 KB)

Published:

15 October 2014

Psoriasis (plaque, moderate to severe) - secukinumab: comments table

Psoriasis (plaque, moderate to severe) - secukinumab: comments table
Psoriasis (plaque, moderate to severe) - secukinumab: comments table (PDF 95 KB)

Published:

15 October 2014

Psoriasis (plaque, moderate to severe) - secukinumab: final matrix

Psoriasis (plaque, moderate to severe) - secukinumab: final matrix
Psoriasis (plaque, moderate to severe) - secukinumab: final matrix (PDF 25 KB)

Published:

15 October 2014

Psoriasis (plaque, moderate to severe) - secukinumab: final scope

Psoriasis (plaque, moderate to severe) - secukinumab: final scope
Psoriasis (plaque, moderate to severe) - secukinumab: final scope (PDF 34 KB)

Published:

15 October 2014

Psoriasis (plaque, moderate to severe) - secukinumab: draft scope for consultation (pre-referral) - October 2013

Psoriasis (plaque, moderate to severe) - secukinumab: draft scope for consultation (pre-referral) - October 2013
Psoriasis (plaque, moderate to severe) - secukinumab: draft scope for consultation (pre-referral) - October 2013 (PDF 106 KB)

Published:

26 March 2014

Psoriasis (plaque, moderate to severe) - secukinumab: provisional matrix (pre-referral) - October 2013

Psoriasis (plaque, moderate to severe) - secukinumab: provisional matrix (pre-referral) - October 2013
Psoriasis (plaque, moderate to severe) - secukinumab: provisional matrix (pre-referral) - October 2013 (PDF 97 KB)

Published:

26 March 2014